Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

AR-V7 Biomarker Test Remains on the Wish List for CRPC

August 20th 2017

The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies.

Dr. Higano on Combinations With Radium-223 for Prostate Cancer

August 18th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses risks associated with combining radium-223 dichloride (Xofigo) for patients with prostate cancer.

Drake Discusses Immunomodulatory Therapies

August 18th 2017

Charles Drake, MD, PhD, shares his insight on the promise and challenges with immunomodulatory drugs, and immune-activating agents in prostate cancer.

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

August 18th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

August 17th 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

Dr. Brawer on the Significance of the Prolaris Genetic Test for Prostate

August 17th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

August 16th 2017

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy, resulting in a rapid evolution of genetic testing that is poised to revolutionize the diagnosis and care of at-risk men as well as those who have the disease.

Dr. Choyke Discusses Screening in Prostate Cancer

August 16th 2017

Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.

Dr. Choyke on Developments for the Screening of Prostate Cancer

August 15th 2017

Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.

Loeb Discusses Genomic Testing and Accurate Prostate Cancer Staging

August 11th 2017

Stacy Loeb, MD, discusses the promise and challenges with genomic testing in prostate cancer.

The Clinical Value of MRI Testing in Prostate Cancer

August 11th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.

Expert Discusses QOL at 2 Years Following Prostate Cancer Treatment

August 10th 2017

Andrew Stephenson, MD, discusses the impact of various approaches—radiation, surgery, and active surveillance—on patients’ quality of life 2 years following treatment.

Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer

August 10th 2017

Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival outcomes when treated with early docetaxel.

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Stephenson on Advancements of Treatment for Prostate Cancer

August 10th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses advancements being made in the field of prostate cancer.

Dr. Feldman on Managing Patients With Prostate Cancer Under Active Surveillance

August 9th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses managing patients with prostate cancer under active surveillance.

Dr. Choi on Considering Factors for RT in Prostate Cancer

August 7th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Using Population Science to Fill in the Blanks

August 7th 2017

When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 4th 2017

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.